AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04281576
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab (HER-2 positive patients only) intravenous infusion will be administered once every 3 weeks on Day 1 of each cycle. First dose is 8mg/kg, followed by 6 mg/kg.
Trial: NCT03081923
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: anti-PD-L1 mono therapy
Trial: NCT03081923
Drug: Tremelimumab
RxNorm normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-CTLA4 drug Tremelimumab mono therapy
Trial: NCT03951415
Drug: PARP inhibitor and Anti-PD-L1
RxNorm normalized name: anti-inhibitor coagulant complex
DrugBank: Anti-inhibitor coagulant complex (DB13151)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olaparib tablets 300mg twice daily orally and durvalumab 1500mg by IV infusion every 4 weeks
Trial: NCT00004061
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004061
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04697992
Drug: vitamin c 20%
RxNorm normalized name: DIMETHICONE 30 mg in 1 mL TOPICAL CREAM [AnYi Beauty Vitamin C 20% Cream]
DrugBank: Dimethicone (DB11074)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one eye was treated with vitamin c 20% + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling).
Trial: NCT04697992
Drug: Tranexamic acid 5mg/ml
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one eye was treated with tranexamin acid 5 mg/ml + microneedling a session was done every 2 weeks a total of 4 sessions (other eye was placebo treated with saline + microneedling)
Trial: NCT03303066
Drug: FG-4592
RxNorm normalized name: (6aR,9R)-7-Methyl-4,6,6a,7,8,9-hexahydro-indolo[4,3-fg]quinoline-9-carboxylic acid ((S)-2-hydroxy-1-methyl-ethyl)-amide
DrugBank: Ergometrine (DB01253)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02810132
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: See above
Trial: NCT01682720
Drug: RBV
RxNorm normalized name: RBV
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Trial: NCT01260311
Drug: Fesoterodine
RxNorm normalized name: Fesoterodine
DrugBank: Fesoterodine (DB06702)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Any dose of Fesoterodine
Trial: NCT02242409
Drug: Gemcitabine and Abraxane
RxNorm normalized name: Abraxane
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000 mg/m2 followed by abraxane 125 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
Trial: NCT02527083
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02527083
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02527083
Drug: Ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00625729
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day -6 through day -2, 25 mg/m\^2 intravenous (IV)
Trial: NCT01874171
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01874171
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01927861
Drug: somatropin
RxNorm normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.
Trial: NCT02349828
Drug: Acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01742052
Drug: MT-1303-Low
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01742052
Drug: MT-1303-Middle
RxNorm normalized name: WHEAT MIDDLINGS
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01742052
Drug: MT-1303-High
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03412773
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg once every 3 weeks (Q3W), intravenous dosing (IV)
Trial: NCT03412773
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg twice daily (BID), oral dosing
Trial: NCT01656720
Drug: 1R, 2S-methoxamine hydrochloride
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01509209
Drug: Pseudoephedrine / Levocetirizine
DrugBank: Cetirizine (DB00341)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablet, BID everyday
Trial: NCT01766089
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexmedetomidine (0.4 µg/kg/h) starting 20 before induction of anaesthesia and continued until peritoneal closure
Trial: NCT01171937
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: children get randomized to either placebo or active risperidone
Trial: NCT00251966
Drug: Esomeprazole
RxNorm normalized name: Esomeprazole
DrugBank: Esomeprazole (DB00736)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01340118
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: once daily inhalation with 400 µg budesonide (dry powder)during 6 weeks
Trial: NCT03978156
Drug: Dronabinol 2.5 MG
RxNorm normalized name: dronabinol 2.5 MG
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will take dronabinol daily during 2 week dosing period separated by a one week washout period.
Trial: NCT03978156
Drug: Microcrystalline cellulose
RxNorm normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take placebo daily during 2 week dosing period separated by a one week washout period.
Trial: NCT01064284
Drug: Recombinant FVIII
RxNorm normalized name: HUMAN COAGULATION FACTOR VIII (FVIII, ANTIHEMOPHILIC FACTOR, AHF, PROCOAGULANT COMPONENT) WITH DELETED B-DOMAIN (746-1639)-SEQUENCE: SINGLE-CHAIN RECOMBINANT FVIII COMPOSED OF DOMAINS A1-A1-A2-A2 (1-740), THE B-DOMAIN N-AND C-TERMINAL FRAGMENTS (741-745)
DrugBank: Omfiloctocog alfa (DB19229)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
Trial: NCT00378287
Drug: rabeprazole sodium
RxNorm normalized name: Rabeprazole Sodium
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02677051
Drug: Sulforaphane
RxNorm normalized name: Sulforaphane
DrugBank: Sulforaphane (DB12422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulforaphane (1-isothiocyanato-4R- (methylsulfinyl)butane) is an isothiocyanate derived from the action of the plant enzyme myrosinase on glucosinolates including glucoraphanin and comes from consumption of many cruciferous vegetables.
Trial: NCT03192332
Drug: Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA)
DrugBank: Plasminogen (DB16701)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bridging thrombolysis (IV t-PA plus mechanical thrombectomy) according to current European and North American stroke guidelines.
Trial: NCT03657407
Drug: Belladonna Opium
RxNorm normalized name: belladonna alkaloids / opium
DrugBank: Opium (DB11130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Belladonna Opium 16.2-60mg rectal suppository
Trial: NCT03657407
Drug: Glycerin Suppository
RxNorm normalized name: Leader Pediatric Glycerin Suppository
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerine rectal suppository
Trial: NCT00694928
Drug: butoconazole nitrate
RxNorm normalized name: Butoconazole Nitrate
DrugBank: Butoconazole (DB00639)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: semi-solid, single dose
Trial: NCT01670149
Drug: Rifaximin
RxNorm normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT04150757
Drug: Intranasal ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients with vaso-occlusive episode and sickle cell disease in moderate to severe pain determined at triage will receive intranasal ketamine while awaiting IV placement.
Trial: NCT03568058
Drug: personalized vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.
Trial: NCT03568058
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200 mg pembrolizumab will be administered intravenous (IV) infusion every 3 weeks.
Trial: NCT00231465
Drug: docetaxel (Taxotere®)
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Taxotere® will be administered to patients a maximum of 2 cycles, after a maximal response is achieved, and then discontinued.
Trial: NCT04380753
Drug: AMG 510
RxNorm normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be enrolled and will receive AMG 510 PO QD.
Trial: NCT01260415
Drug: Panitumumab, Oxaliplatin, 5-FU
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: * Panitumumab 6 mg / kg, given over 60 minutes~* Oxaliplatin 85 mg / m2 combined with leucovorin 400 mg / m2, given over 2 hours OR~* Irinotecan 180 mg / m2 , given over 90 minutes, concurrent with leucovorin 400 mg / m2, given over 90 minutes~* 5FU 400 mg / m2, by bolus infusion~* 5FU 2400 mg / m2, given over 46 hours
Trial: NCT01720602
Drug: vorinostat
RxNorm normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01720602
Drug: anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01720602
Drug: letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01720602
Drug: exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT00902369
Drug: AK106-001616
RxNorm normalized name: AK106-001616
DrugBank: AK106-001616 (DB16058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part1: Dose escalation Part2: Dose expansion
Trial: NCT00902369
Drug: Active comparator
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00250575
Drug: Clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00029900
Drug: ADI PEG
RxNorm normalized name: ADI-PEG 20
DrugBank: Pegargiminase (DB06592)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01044693
Drug: Nebivolol 5 mg
RxNorm normalized name: nebivolol 5 MG
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nebivolol 5mg single oral dose
Trial: NCT01044693
Drug: metoprolol tartrate 50 mg
RxNorm normalized name: metoprolol tartrate 50 MG
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: metoprolol tartrate 50 mg single oral dose
Trial: NCT01044693
Drug: Sildenafil25 mg
RxNorm normalized name: sildenafil 25 MG
DrugBank: Sildenafil (DB00203)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sildenafil 25 mg single oral dose
Trial: NCT00620802
Drug: CGT-2168
RxNorm normalized name: CGT
DrugBank: Cycloguanil (DB14763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (CGT-2168, one capsule each daily)
Trial: NCT00620802
Drug: Plavix
RxNorm normalized name: Plavix
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: (clopidogrel, 75 mg)
Trial: NCT00544687
Drug: CRx-191
RxNorm normalized name: CRx-119
DrugBank: CRx-119 (DB05688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical (mometasone furoate + nortriptyline HCl)
Trial: NCT00544687
Drug: mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: topical mometasone furoate
Trial: NCT00544687
Drug: nortriptyline HCl
RxNorm normalized name: nortriptyline HCl
DrugBank: Nortriptyline (DB00540)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: topical nortriptyline HCl
Trial: NCT03765021
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One side of the face will be assigned to TXA intradermal microinjection using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml syringe with 100mg/ml. TXA will prepared under sterile conditions. Injections will be applied intradermally on hyperpigmented areas at 1cm intervals. The injection will be repeated every two weeks for three months.
Trial: NCT01570907
Drug: Quetiapine Fumarate
RxNorm normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg tablet
Trial: NCT01977235
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01977235
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01483430
Drug: Ginseol Kg1 (low dose)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 capsule/day (100mg of Ginseol Kg1), Duration: 8 weeks
Trial: NCT02714543
Drug: Hyaluronic Acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: injection hyaluronic acid 1500IU once a week for 6 weeks
Trial: NCT02714543
Drug: aloevera gel
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: aloevera gel one scoop to be applied 3-4 times daily for 3 months
Trial: NCT02425176
Drug: Botulinum toxin A (BoNT-A) 50U
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Drug intervention:~The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.~Drug is only injected once at baseline
Trial: NCT02425176
Drug: Botulinum toxin A (BoNT-A) 100U
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
Trial: NCT02425176
Drug: Botulinum toxin A (BoNT-A) 200U
RxNorm normalized name: Botulinum toxin A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
Trial: NCT01483430
Drug: Ginseol Kg1(high dose)
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule/day (300mg of Ginseol Kg1), Duration: 8 weeks
Trial: NCT02658422
Drug: Test Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Test Montelukast (GW483100) is available as round, biconvex, pink 10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water.
Trial: NCT00400088
Drug: paroxetine
RxNorm normalized name: Paroxetine
DrugBank: Paroxetine (DB00715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Start at 20 mg po od. Increase dose to 40 mg po od at week 4 if there is less than 20 % reduction in MADRS scores.
Trial: NCT00400088
Drug: lithium
RxNorm normalized name: Lithium
DrugBank: Lithium citrate (DB14507)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: start at 600mg po hs with dose to be flexibly titrated to a serum level of between 0.6 and 1.1 mmol/l.
Trial: NCT03760666
Drug: Brequinar/Brequinar + Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The first 14 participants had brequinar monotherapy; the final 3 subjects were also exposed to a combination of brequinar + ribavirin.
Trial: NCT02658422
Drug: Reference Montelukast
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reference Montelukast (innovator product) is available as pale beige, rounded square shaped,10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water. Singular is the innovator product used for this study, which is a trade name owned by Merck Sharp and Dohme Corporation.
Trial: NCT01913912
Drug: LDX.
RxNorm normalized name: Lisdexamfetamine
DrugBank: Lisdexamfetamine (DB01255)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In this study 3 different doses of LDX will be used:~* 30 mg capsules: 30 mg LDX, equivalent to 8.9 mg of dexamphetamine~* 50 mg capsules: 50 mg LDX, equivalent to 14.8 mg of dexamphetamine~* 70 mg capsules: 70 mg LDX, equivalent to 20.8 mg of dexamphetamine
Trial: NCT02408770
Drug: ulipristal acetate
RxNorm normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: selective progesterone receptor modulator
Trial: NCT00383851
Drug: ATN-224
RxNorm normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00383851
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00563563
Drug: NB32
RxNorm normalized name: Nalbuphine
DrugBank: Nalbuphine (DB00844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.
Trial: NCT01913912
Drug: sugar pill
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Children will take once only a placebo capsule during the DBPC phase (phase 4) the morning of the testing. For blinding purpose we will blindfold the children when taking placebo.
Trial: NCT00283985
Drug: Kidrolase
RxNorm normalized name: Folate hydrolase G2
DrugBank: Asparaginase Escherichia coli (DB00023)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6000 u/ m2 IM at J2, J4 and J6 and J8. 3 to 6 cycles.
Trial: NCT00283985
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg/ per os at J1, J2 and J4.
Trial: NCT00283985
Drug: Erwinase
RxNorm normalized name: Erwinase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In case of allergy to Kidrolase~20000 u/m2 en IM at J2, J4, J6 et J8. 3 to 6 cycles
Trial: NCT00088881
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00088881
Drug: vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02661347
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
Trial: NCT02596893
Drug: GED-0301
RxNorm normalized name: GED-0507-34-Levo
DrugBank: GED-0507-34-Levo (DB16109)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04038008
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluconazole is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 200 mg of fluconazole.
Trial: NCT01265147
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40mg/m2/w
Trial: NCT01265147
Drug: Nedaplatin
RxNorm normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg/m2/w
Trial: NCT00720083
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00720083
Drug: vandetanib
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally